1. Home
  2. RMCO vs IMMP Comparison

RMCO vs IMMP Comparison

Compare RMCO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royalty Management Holding Corporation

RMCO

Royalty Management Holding Corporation

N/A

Current Price

$2.03

Market Cap

35.2M

Sector

Miscellaneous

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

SELL

Current Price

$3.11

Market Cap

31.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RMCO
IMMP
Founded
2021
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.2M
31.5M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
RMCO
IMMP
Price
$2.03
$3.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.2K
★ 30.6K
Earning Date
11-13-2026
09-01-2026
Dividend Yield
★ 0.49%
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $4,949,916.00
N/A
Revenue This Year
$61.62
N/A
Revenue Next Year
$62.50
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 513.30
N/A
52 Week Low
$1.74
$0.26
52 Week High
$5.00
$5.36

Technical Indicators

Market Signals
Indicator
RMCO
IMMP
Relative Strength Index (RSI) 40.15 49.75
Support Level $1.90 $3.06
Resistance Level $2.46 $3.55
Average True Range (ATR) 0.14 0.34
MACD -0.00 -0.05
Stochastic Oscillator 38.00 41.09

Price Performance

Historical Comparison
RMCO
IMMP

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: